Influence of delayed CSF storage on concentrations of phospho-tau protein (181), total tau protein and beta-amyloid (1-42)

被引:30
作者
Kaiser, Elmar [1 ]
Schoenknecht, Peter [1 ]
Thomann, Philipp A. [1 ]
Hunt, Aoife [1 ]
Schroeder, Johannes [1 ]
机构
[1] Univ Heidelberg, Sect Geriatr Psychiat, Dept Psychiat, D-69115 Heidelberg, Germany
关键词
Alzheimer's disease; tau proteins; beta-amyloid; CSF samples; storage conditions;
D O I
10.1016/j.neulet.2007.02.045
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
It is generally accepted that cerebrospinal fluid (CSF) biomarkers such as tau protein, phosphorylated tau protein (threonine 18 1) and beta-amyloid (1-42) can facilitate early and differential diagnosis of Alzheimer's disease (AD). Since the respective concentrations can only be measured in a number of specialized centers, time to CSF specimen work-up has been considered as crucial for the stability of the respective biomarkers. When shipping of CSF samples is needed for biomarker measurement and immediate freezing of samples is not available, an overnight delay of up to 24h frequently occurs. Therefore, we investigated the potential impact of a 24h delayed freezing on CSF biomarker concentrations and compared it to 2h storage (room temperature, 20 degrees C) and an immediate freezing. First, storage at room temperature for 2 h had only marginal, non-significant effects on the concentrations of CSF total tau protein and phospho-tau protein (18 1) compared to immediate freezing. Second, storage at room temperature for 24 h did not significantly affect total tau protein or phospho-tau protein but beta-amyloid (1-42) concentrations which increased significantly compared to the samples frozen immediately. These results indicate that CSF samples for the evaluation of total tau and phospho-tau protein may be kept at room temperature for up to 24h whereas CSF samples for beta-amyloid (1-42) need to be frozen immediately. (c) 2007 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:193 / 195
页数:3
相关论文
共 7 条
[1]   Cerebrospinal fluid tau and Aβ42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment [J].
Andreasen, N ;
Minthon, L ;
Vanmechelen, E ;
Vanderstichele, H ;
Davidsson, P ;
Winblad, B ;
Blennow, K .
NEUROSCIENCE LETTERS, 1999, 273 (01) :5-8
[2]   CSF markers for incipient Alzheimer's disease [J].
Blennow, K ;
Hampel, H .
LANCET NEUROLOGY, 2003, 2 (10) :605-613
[3]   Levels of total tau and tau protein phosphorylated at threonine 181 in patients with incipient and manifest Alzheimer's disease [J].
Schönknecht, P ;
Pantel, J ;
Hunt, A ;
Volkmann, M ;
Buerger, K ;
Hampel, H ;
Schröder, J .
NEUROSCIENCE LETTERS, 2003, 339 (02) :172-174
[4]   Effects of processing and storage conditions on amyloid β (1-42) and tau concentrations in cerebrospinal fluid:: Implications for use in clinical practice [J].
Schoonenboom, NSM ;
Mulder, C ;
Vanderstichele, H ;
Van Elk, EJ ;
Kok, A ;
Van Kamp, GJ ;
Scheltens, P ;
Blankenstein, MA .
CLINICAL CHEMISTRY, 2005, 51 (01) :189-195
[5]  
Sjögren M, 2001, CLIN CHEM, V47, P1776
[6]   Standardization of measurement of β-amyloid(1-42) in cerebrospinal fluid and plasma [J].
Vanderstichele, H ;
Van Kerschaver, E ;
Hesse, C ;
Davidsson, P ;
Buyse, MA ;
Andreasen, N ;
Minthon, L ;
Wallin, A ;
Blennow, K ;
Vanmechelen, E .
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2000, 7 (04) :245-258
[7]   Consensus paper of the WFSBP Task Force on biological markers of dementia:: The role of CSF and blood analysis in the early and differential diagnosis of dementia [J].
Wiltfang, J ;
Lewczuk, P ;
Riederer, P ;
Grünblatt, E ;
Hock, C ;
Scheltens, P ;
Hampel, H ;
Vanderstichele, H ;
Iqbal, K ;
Galasko, D ;
Lannfelt, L ;
Otto, M ;
Esselmann, H ;
Henkel, AW ;
Kornhuber, J ;
Blennow, K .
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2005, 6 (02) :69-84